Long-term effects of intermittent equine parathyroid hormone fragment (ePTH-1-37) administration on bone metabolism in healthy horses

Intermittent administration of parathyroid hormone (PTH) is an anabolic therapy for osteoporotic conditions in humans. This study evaluated the effects of equine PTH fragment (ePTH-1-37) administration on bone metabolism in 12 healthy horses. Six horses each were treated once daily for 120days with...

Full description

Saved in:
Bibliographic Details
Published in:The veterinary journal (1997) 2011-11, Vol.190 (2), p.e130-e134
Main Authors: Weisrock, Katharina U., Winkelsett, Sarah, Martin-Rosset, William, Forssmann, Wolf-Georg, Parvizi, Nahid, Coenen, Manfred, Vervuert, Ingrid
Format: Article
Language:English
Subjects:
Absorptiometry, Photon - veterinary
adverse effects
alkaline phosphatase
Animals
Biomarkers - metabolism
blood serum
Bone
Bone and Bones - drug effects
Bone and Bones - metabolism
bone density
Bone Density - drug effects
Bone marker
Bone mineral density
bone resorption
calcium
collagen
crosslinking
Drug Administration Schedule - veterinary
dual-energy X-ray absorptiometry
Horse
horses
Horses - metabolism
humans
Injections, Subcutaneous - veterinary
inorganic phosphorus
ionization
long term effects
Male
metacarpus
osteocalcin
parathyroid hormone
Parathyroid Hormone - administration & dosage
Parathyroid Hormone - pharmacology
Parathyroid hormone fragment (PTH-1-37)
Peptide Fragments - administration & dosage
Peptide Fragments - pharmacology
therapeutics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intermittent administration of parathyroid hormone (PTH) is an anabolic therapy for osteoporotic conditions in humans. This study evaluated the effects of equine PTH fragment (ePTH-1-37) administration on bone metabolism in 12 healthy horses. Six horses each were treated once daily for 120days with subcutaneous injections of 0.5μg/kg ePTH-1-37 or placebo. Blood was collected to determine ionized calcium (Ca++), total Ca (CaT), inorganic phosphorus, serum equine osteocalcin (eOC), carboxy-terminal telopeptide of type I collagen (ICTP), bone-specific alkaline phosphatase, and carboxy-terminal cross-linked telopeptide of type I collagen. Bone mineral density (BMD) was determined with dual X-ray absorptiometry of the metacarpus and calcaneus. Significantly higher blood Ca++ and plasma CaT concentrations were measured 5h after ePTH-1-37 administration compared to placebo. Higher serum eOC concentrations were found for ePTH-1-37 treatment at days 90 (P
ISSN:1090-0233
1532-2971
DOI:10.1016/j.tvjl.2010.12.032